Non-consolidated Financial Results
for the Fiscal Year Ended June 30, 2013
[Japanese GAAP]

August 13, 2013

Company Name: PeptiDream Inc. Tokyo Stock Exchange
Stock Code: 4587 URL http://www.peptidream.com/
Representative: Kiichi Kubota, Chief Executive Officer
Inquiries: Yoshiyuki Sekine, Director of Management Administration TEL: +81-3-3485-7707
Scheduled date of Ordinary General Meeting of Shareholders: September 26, 2013
Scheduled filing date for Securities Report: September 27, 2013
Scheduled starting date of dividend payments: —
Supplementary briefing materials on financial results: No
Explanatory meeting on financial results: Yes (for institutional investors)

(Amounts of less than one million yen are rounded down)

1. Financial Results for the Fiscal Year Ended June 30, 2013 (July 1, 2012 to June 30, 2013)

(1) Operating results (% indicates changes from the previous corresponding period)

	Net sales		Operating income		Ordinary income		Net income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Fiscal Year ended June 30, 2013	678	152.1	160	-	174	-	137	-
Fiscal Year ended June 30, 2012	269	(55.3)	(18)	-	(21)	-	9	(94.3)

	Net income per share	Diluted net income per share	Return on equity	Ordinary income to total assets	Operating income to net sales
	Yen	Yen	%	%	%
Fiscal Year ended June 30, 2013	12.32	9.86	4.6	5.5	23.7
Fiscal Year ended June 30, 2012	0.93	-	3.0	-	-

(Reference) Equity in earnings (losses) of affiliates Fiscal Year ended June 30, 2013: - million yen
Fiscal Year ended June 30, 2012: - million yen

(Notes)
1. The Company conducted a 100-for-1 stock split of its common stock effective February 13, 2013 where 100 shares constitute 1 share unit, and net income per share has been calculated as if the stock split was conducted at the beginning of the previous fiscal year.
2. Ordinary income to total assets and operating income to net sales are not stated as the Company recorded an ordinary loss and operating loss for the fiscal year ended June 30, 2012.
3. As the Company became listed on the Mothers section of the Tokyo Stock Exchange on June 11, 2013, diluted net income per share for the fiscal year ended June 30, 2013 is calculated by assuming the average of the stock price between the day of the listing to June 30, 2013 as the average stock price for the fiscal year ended June 30, 2013.

(2) Financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of June 30, 2013	5,926	5,696	96.1	429.96
As of June 30, 2012	405	327	79.9	30.30

(Reference) Equity As of June 30, 2013: 5,693 million yen
As of June 30, 2012: 324 million yen

(Note) The Company conducted a 100-for-1 stock split of its common stock effective February 13, 2013 where 100 shares constitute 1 share unit, and net assets per share has been calculated as if the stock split was conducted at the beginning of the previous fiscal year.

(3) Cash flows

	Cash flow from operating activities	Cash flow from investing activities	Cash flow from financing activities	Balance of cash and cash equivalents
	Million yen	Million yen	Million yen	Million yen
Fiscal Year ended June 30, 2013	234	(112)	5,187	5,572
Fiscal Year ended June 30, 2012	(150)	(56)	(16)	229

2. Payment of Dividends

	Annual dividends					Total dividends (Annual)	Dividend payout ratio	Dividends to net assets
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
Fiscal Year ended June 30, 2012	-	0.00	-	0.00	0.00	-	-	-
Fiscal Year ended June 30, 2013	-	0.00	-	0.00	0.00	-	-	-
Fiscal Year ending June 30, 2014 (forecast)	-	0.00	-	0.00	0.00		-	

3. Financial Forecasts for the Fiscal Year Ending June 30, 2014 (July 1, 2013 to June 30, 2014)

(% indicates changes from the previous corresponding period)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full Year	1,385	104.3	718	347.1	714	310.3	442	222.9	33.45

(Note) As business results are managed by year, only forecasts for the full year are posted.

[Notes]

(1) Changes in accounting policies, changes in accounting estimates and retrospective restatements

1) Changes in accounting policies due to amendment to the accounting standards, etc.	:	None
2) Changes in accounting policies other than 1) above	:	None
3) Changes in accounting estimates	:	None
4) Retrospective restatements	:	None

(2) Number of shares issued (common stock)

1) Number of shares issued at the end of the period (including treasury stock)	As of June 30, 2013	13,241,300 shares	As of June 30, 2012	107,000 shares
2) Number of treasury stock at the end of the period	As of June 30, 2013	- shares	As of June 30, 2012	- shares
3) Average number of shares during the period	Fiscal Year ended June 30, 2013	11,131,038 shares	Fiscal Year ended June 30, 2012	107,000 shares

(Note) As a result of the allocation of new shares to a third party to Novartis Pharma AG conducted on November 13, 2012, the number of shares increased to 5,263 shares and the number of shares issued became 112,263 shares. Along with the 100-for-1 stock split of common stock conducted on February 13, 2013, the number of shares increased to 11,114,037 shares and the number of shares issued became 11,226,300 shares. Along with the public offering from becoming listed on the Mothers section of the Tokyo Stock Exchange and the allocation of new shares to a third party related to overallotment, the number of shares increased to 2,015,000 shares and the number of shares issued became 13,241,300 shares.

*Indication of the status of execution of audit procedures

As these financial results are not subject to audit procedures pursuant to the Financial Instruments and Exchange Act, the said audit procedures have not been completed at the time of disclosure of this report.

*Explanation on the appropriate use of operating forecasts and other special instructions

- Financial forecasts and other statements regarding the future presented in these materials are based on information currently available and certain assumptions deemed to be reasonable, and are not meant to be taken as commitment of the Company to achieve such results. Actual performance may differ substantially due to various factors.
- The Company plans to hold an explanatory meeting on financial results for institutional investors on August 23, 2013.